CN105121462B - 稳定化的胰岛素样生长因子多肽 - Google Patents

稳定化的胰岛素样生长因子多肽 Download PDF

Info

Publication number
CN105121462B
CN105121462B CN201380066090.8A CN201380066090A CN105121462B CN 105121462 B CN105121462 B CN 105121462B CN 201380066090 A CN201380066090 A CN 201380066090A CN 105121462 B CN105121462 B CN 105121462B
Authority
CN
China
Prior art keywords
deleted
amino acid
igf
amino acids
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380066090.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN105121462A (zh
Inventor
M·弗纳罗
T·胡贝尔
M·祖里尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50073229&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN105121462(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN105121462A publication Critical patent/CN105121462A/zh
Application granted granted Critical
Publication of CN105121462B publication Critical patent/CN105121462B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/65Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201380066090.8A 2012-12-18 2013-12-16 稳定化的胰岛素样生长因子多肽 Active CN105121462B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261738475P 2012-12-18 2012-12-18
US61/738,475 2012-12-18
PCT/IB2013/060985 WO2014097116A1 (en) 2012-12-18 2013-12-16 Stabilized insulin-like growth factor polypeptides

Publications (2)

Publication Number Publication Date
CN105121462A CN105121462A (zh) 2015-12-02
CN105121462B true CN105121462B (zh) 2019-08-02

Family

ID=50073229

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380066090.8A Active CN105121462B (zh) 2012-12-18 2013-12-16 稳定化的胰岛素样生长因子多肽

Country Status (36)

Country Link
US (1) US10167329B2 (https=)
EP (2) EP3626735A1 (https=)
JP (1) JP6499080B2 (https=)
KR (1) KR102182523B1 (https=)
CN (1) CN105121462B (https=)
AP (1) AP2015008440A0 (https=)
AU (1) AU2013365796B2 (https=)
BR (1) BR112015013708B1 (https=)
CA (1) CA2894976C (https=)
CL (1) CL2015001708A1 (https=)
CR (2) CR20200079A (https=)
CU (1) CU24308B1 (https=)
CY (1) CY1122309T1 (https=)
DK (1) DK2935320T3 (https=)
EA (1) EA034356B1 (https=)
EC (1) ECSP15031046A (https=)
ES (1) ES2756330T3 (https=)
GT (1) GT201500168A (https=)
HR (1) HRP20191965T1 (https=)
HU (1) HUE047386T2 (https=)
IL (1) IL239387A0 (https=)
LT (1) LT2935320T (https=)
MA (1) MA38153B1 (https=)
MX (1) MX363021B (https=)
MY (1) MY174820A (https=)
NZ (1) NZ708091A (https=)
PE (2) PE20200894A1 (https=)
PH (1) PH12015501271A1 (https=)
PL (1) PL2935320T3 (https=)
PT (1) PT2935320T (https=)
RS (1) RS59545B1 (https=)
SA (1) SA515360603B1 (https=)
SG (1) SG11201503782PA (https=)
SI (1) SI2935320T1 (https=)
TN (1) TN2015000182A1 (https=)
WO (1) WO2014097116A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160271265A1 (en) * 2013-10-02 2016-09-22 Novartis Ag Insulin-like growth factor mimetics for use in therapy
SG11201807400TA (en) * 2016-03-04 2018-09-27 Shire Human Genetic Therapies Recombinant follistatin-fc fusion proteins and use in treating duchenne muscular dystrophy
US10953074B2 (en) * 2017-01-08 2021-03-23 Richard D. Lippman Composition and method for improving sensorineural hearing
EP3569614A1 (en) 2018-05-18 2019-11-20 Julius-Maximilians-Universität Würzburg Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase
EP4606428A3 (en) * 2018-06-27 2025-11-05 Juvena Therapeutics, Inc. Heparin-associated polypeptides and uses thereof
CN109053875B (zh) * 2018-08-31 2021-06-29 重庆大学 突变型igf-1、重组质粒、重组蛋白及应用
RU2711111C1 (ru) * 2018-09-05 2020-01-15 Илья Владимирович Духовлинов Гибридный белок igf-1-long для лечения инсульта, нуклеиновая кислота, вектор, клетка, фармацевтическая композиция, способ лечения
CN110642937B (zh) * 2019-10-11 2021-04-06 南开大学 多肽衍生物、纳米纤维及其应用
CN115379850A (zh) 2019-12-24 2022-11-22 裘美娜治疗公司 再生性多肽及其用途
WO2022271466A1 (en) 2021-06-21 2022-12-29 Juvena Therapeutics, Inc. Regenerative polypeptides and uses thereof
WO2025106529A2 (en) * 2023-11-14 2025-05-22 Cavalry Biosciences, Inc. Compositions for targeting muscle cells and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000040612A1 (en) * 1999-01-06 2000-07-13 Genentech, Inc. Insulin-like growth factor (igf) i mutant variants
WO2006074390A2 (en) * 2005-01-07 2006-07-13 Regeneron Pharmaceuticals, Inc. Methods of treating obesity with combination therapeautics of igf-i fusion polypeptides
CN101466399A (zh) * 2006-06-09 2009-06-24 诺瓦提斯公司 稳定的胰岛素样生长因子多肽
WO2011011073A1 (en) * 2009-07-22 2011-01-27 Ipsen Pharma S.A.S. Site-specific pegylated or site-specific lipidated igf-1 and analogues of igf-1

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
AU762351B2 (en) 1999-01-06 2003-06-26 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
WO2002085923A2 (en) 2001-04-19 2002-10-31 The Scripps Research Institute In vivo incorporation of unnatural amino acids
US7355018B2 (en) 2003-09-30 2008-04-08 Regeneron Pharmaceuticals, Inc. Modified IGF1 polypeptides with increased stability and potency
EP1674113A1 (en) 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)
US7521211B2 (en) * 2005-04-05 2009-04-21 Regeneron Pharmaceuticals, Inc IGF-1 and IGF-2 chimeric polypeptides and therapeutic uses thereof
KR101459789B1 (ko) 2006-06-09 2014-11-07 노파르티스 아게 안정화된 인슐린-유사 성장 인자 폴리펩티드
PL3075858T3 (pl) 2007-12-21 2020-07-13 Novartis Ag Ssaczy wektor ekspresyjny
PE20120532A1 (es) 2009-04-27 2012-05-18 Novartis Ag ANTICUERPOS ANTI-ActRIIB
WO2011011071A2 (en) 2009-07-22 2011-01-27 Ipsen Pharma S.A.S. Analogues of insulin-like growth factor-1 (igf-1)
US10030063B2 (en) 2012-12-18 2018-07-24 Novartis Ag Production of therapeutic proteins in genetically modified mammalian cells
US20160271265A1 (en) 2013-10-02 2016-09-22 Novartis Ag Insulin-like growth factor mimetics for use in therapy
UY35874A (es) 2013-12-12 2015-07-31 Novartis Ag Un proceso para la preparación de una composición de proteínas pegiladas

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000040612A1 (en) * 1999-01-06 2000-07-13 Genentech, Inc. Insulin-like growth factor (igf) i mutant variants
WO2006074390A2 (en) * 2005-01-07 2006-07-13 Regeneron Pharmaceuticals, Inc. Methods of treating obesity with combination therapeautics of igf-i fusion polypeptides
CN101466399A (zh) * 2006-06-09 2009-06-24 诺瓦提斯公司 稳定的胰岛素样生长因子多肽
WO2011011073A1 (en) * 2009-07-22 2011-01-27 Ipsen Pharma S.A.S. Site-specific pegylated or site-specific lipidated igf-1 and analogues of igf-1

Also Published As

Publication number Publication date
AP2015008440A0 (en) 2015-05-31
MA38153B1 (fr) 2018-06-29
CU20150064A7 (es) 2016-02-29
US20150329614A1 (en) 2015-11-19
NZ708091A (en) 2018-03-23
KR102182523B1 (ko) 2020-11-25
GT201500168A (es) 2016-01-21
CU24308B1 (es) 2018-01-10
PT2935320T (pt) 2019-11-15
CR20150324A (es) 2015-08-10
HUE047386T2 (hu) 2020-04-28
EA201591165A1 (ru) 2015-11-30
SG11201503782PA (en) 2015-06-29
ES2756330T3 (es) 2020-04-27
EP2935320B1 (en) 2019-08-21
JP2016501025A (ja) 2016-01-18
AU2013365796B2 (en) 2017-03-30
JP6499080B2 (ja) 2019-04-10
ECSP15031046A (es) 2019-03-29
MY174820A (en) 2020-05-17
AU2013365796A1 (en) 2015-05-28
PL2935320T3 (pl) 2020-03-31
EP3626735A1 (en) 2020-03-25
IL239387A0 (en) 2015-07-30
CY1122309T1 (el) 2021-01-27
CL2015001708A1 (es) 2015-08-28
BR112015013708B1 (pt) 2022-10-18
US10167329B2 (en) 2019-01-01
LT2935320T (lt) 2019-11-11
CR20200079A (es) 2020-03-21
EA034356B1 (ru) 2020-01-30
MX2015007932A (es) 2015-10-05
RS59545B1 (sr) 2019-12-31
HK1212712A1 (en) 2016-06-17
TN2015000182A1 (en) 2016-10-03
CA2894976A1 (en) 2014-06-26
HRP20191965T1 (hr) 2020-01-24
CN105121462A (zh) 2015-12-02
PE20151612A1 (es) 2015-11-19
SA515360603B1 (ar) 2020-07-26
MX363021B (es) 2019-03-05
PH12015501271B1 (en) 2015-08-24
BR112015013708A2 (pt) 2017-11-14
DK2935320T3 (da) 2019-11-18
SI2935320T1 (sl) 2019-12-31
EP2935320A1 (en) 2015-10-28
PH12015501271A1 (en) 2015-08-24
KR20150095879A (ko) 2015-08-21
MA38153A1 (fr) 2016-06-30
CA2894976C (en) 2022-10-04
PE20200894A1 (es) 2020-09-08
WO2014097116A1 (en) 2014-06-26

Similar Documents

Publication Publication Date Title
CN105121462B (zh) 稳定化的胰岛素样生长因子多肽
TWI881476B (zh) 結合cd3之抗體
CN111182944B (zh) 双特异性2+1 Contorsbody
JP6621478B2 (ja) 一本鎖Fc融合タンパク質
EP3896083B1 (en) Fc fusion proteins comprising novel linkers or arrangements
CN115812077A (zh) April和baff抑制性免疫调节蛋白及其使用方法
CN104582736A (zh) Fc效应子功能改变的肠降血糖素受体配体多肽Fc区融合多肽和缀合物
CN103492411A (zh) 突变体白介素-2多肽
KR20230025673A (ko) CD3 및 FolR1에 결합하는 항체
KR20240122864A (ko) 효현성 ltbr 항체 및 이들을 포함하는 이중특이적 항체
KR20210121137A (ko) 부갑상선 호르몬 변이체
TW202334245A (zh) 與cd3及plap結合之抗體
HK1212712B (en) Stabilized insulin-like growth factor polypeptides
JP2025511000A (ja) インターフェロンガンマバリアントおよびこれを含む抗原結合分子
CN121358775A (zh) 利用靶向FAP的淋巴毒素β受体激动剂的组合疗法
HK40103089A (zh) 包含磺基葡糖胺磺基水解酶的融合蛋白和其方法
HK40065804A (zh) 甲状旁腺激素变体
HK40075193A (en) Bispecific antibodies comprising a modified c-terminal crossfab fragment

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant